| Drug General Information |
| Drug ID |
D0Y3PH
|
| Former ID |
DNC006798
|
| Drug Name |
9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H8N2O3
|
| Canonical SMILES |
C1=CC2=C(C=C1O)C3=C(N2)C=CC4=C3C(=O)NC4=O
|
| InChI |
1S/C14H8N2O3/c17-6-1-3-9-8(5-6)11-10(15-9)4-2-7-12(11)14(19)16-13(7)18/h1-5,15,17H,(H,16,18,19)
|
| InChIKey |
IJHAYZZOYYQESB-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Serine/threonine-protein kinase Chk1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Wee1-like protein kinase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
HTLV-I infection
|
|
Viral carcinogenesishsa04110:Cell cycle
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
Pathway Interaction Database
|
Fanconi anemia pathway
|
|
p73 transcription factor network
|
|
ATR signaling pathway
|
|
Circadian rhythm pathway
|
|
p53 pathwayplk1_pathway:PLK1 signaling events
|
|
Reactome
|
Activation of ATR in response to replication stress
|
|
Processing of DNA double-strand break ends
|
|
Presynaptic phase of homologous DNA pairing and strand exchange
|
|
G2/M DNA damage checkpoint
|
|
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-156711:Polo-like kinase mediated events
|
|
Cyclin E associated events during G1/S transition
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
G2/M DNA replication checkpoint
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
DNA Damage Response
|
|
Signaling by SCF-KIT
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell Cycle
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP45:G1 to S cell cycle control
|
|
S Phase
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
| References |
| REF 1 | Eur J Med Chem. 2009 Apr;44(4):1383-95. Epub 2008 Sep 30.Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. |
|---|
| REF 2 | J Med Chem. 2006 Aug 10;49(16):4896-911.4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. |
|---|
